Literature DB >> 11606716

Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells.

M Kanovsky1, A Raffo, L Drew, R Rosal, T Do, F K Friedman, P Rubinstein, J Visser, R Robinson, P W Brandt-Rauf, J Michl, R L Fine, M R Pincus.   

Abstract

We have synthesized three peptides from the mdm-2 binding domain of human p53, residues 12-26 (PPLSQETFSDLWKLL), residues 12-20, and 17-26. To enable transport of the peptides across the cell membrane and at the same time to maximize the active mdm-2 binding alpha-helical conformation for these peptides, each was attached at its carboxyl terminus to the penetratin sequence, KKWKMRRNQFWVKVQRG, that contains many positively charged residues that stabilize an alpha-helix when present on its carboxyl terminal end. All three peptides were cytotoxic to human cancer cells in culture, whereas a control, unrelated peptide attached to the same penetratin sequence had no effect on these cell lines. The same three cytotoxic peptides had no effect on the growth of normal cells, including human cord blood-derived stem cells. These peptides were as effective in causing cell death in p53-null cancer cells as in those having mutant or normal p53. Peptide-induced cell death is not accompanied by expression of apoptosis-associated proteins such as Bax and waf(p21). Based on these findings, we conclude that the antiproliferative effects of these p53-derived peptides are not completely dependent on p53 activity and may prove useful as general anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606716      PMCID: PMC60072          DOI: 10.1073/pnas.211280698

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.

Authors:  G Selivanova; V Iotsova; I Okan; M Fritsche; M Ström; B Groner; R C Grafström; K G Wiman
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

2.  Correlation between computed conformational properties of cytochrome c peptides and their antigenicity in a T-lymphocyte proliferation assay.

Authors:  M Vasquez; M R Pincus; H A Scheraga
Journal:  Biopolymers       Date:  1987-03       Impact factor: 2.505

3.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

Review 4.  Biochemical properties and biological effects of p53.

Authors:  R Haffner; M Oren
Journal:  Curr Opin Genet Dev       Date:  1995-02       Impact factor: 5.578

5.  Influence of local interactions on protein structure. I. Conformational energy studies of N-acetyl-N'-methylamides of Pro-X and X-Pro dipeptides.

Authors:  S S Zimmerman; H A Scheraga
Journal:  Biopolymers       Date:  1977-04       Impact factor: 2.505

6.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.

Authors:  G M Clore; J G Omichinski; K Sakaguchi; N Zambrano; H Sakamoto; E Appella; A M Gronenborn
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

Review 7.  P63 and P73: P53 mimics, menaces and more.

Authors:  A Yang; F McKeon
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

8.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

9.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.

Authors:  P Rubinstein; L Dobrila; R E Rosenfield; J W Adamson; G Migliaccio; A R Migliaccio; P E Taylor; C E Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

10.  In vitro differentiation of human granulocyte/macrophage and erythroid progenitors: comparative analysis of the influence of recombinant human erythropoietin, G-CSF, GM-CSF, and IL-3 in serum-supplemented and serum-deprived cultures.

Authors:  G Migliaccio; A R Migliaccio; J W Adamson
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

View more
  20 in total

1.  Introduction of an N-terminal peptide of S100C/A11 into human cells induces apoptotic cell death.

Authors:  Eiichi Makino; Masakiyo Sakaguchi; Keiji Iwatsuki; Nam-ho Huh
Journal:  J Mol Med (Berl)       Date:  2004-07-06       Impact factor: 4.599

2.  Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

Authors:  Ehsan Sarafraz-Yazdi; Wilbur B Bowne; Victor Adler; Kelley A Sookraj; Vernon Wu; Vadim Shteyler; Hunaiz Patel; William Oxbury; Paul Brandt-Rauf; Michael E Zenilman; Josef Michl; Matthew R Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

3.  Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.

Authors:  Hao Yang; Shan Liu; Huawei Cai; Lin Wan; Shengfu Li; Youping Li; Jingqiu Cheng; Xiaofeng Lu
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

4.  NT4(Si)-p53(N15)-antennapedia induces cell death in a human hepatocellular carcinoma cell line.

Authors:  Li-Ping Song; Yue-Ping Li; Ning Wang; Wei-Wei Li; Juan Ren; Shu-Dong Qiu; Quan-Ying Wang; Guang-Xiao Yang
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

5.  Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53.

Authors:  Sachiko Yamada; Hiroshi Kanno; Nobutaka Kawahara
Journal:  J Neurooncol       Date:  2012-04-18       Impact factor: 4.130

6.  D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.

Authors:  Min Liu; Chong Li; Marzena Pazgier; Changqing Li; Yubin Mao; Yifan Lv; Bing Gu; Gang Wei; Weirong Yuan; Changyou Zhan; Wei-Yue Lu; Wuyuan Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

7.  Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.

Authors:  Wilbur B Bowne; Josef Michl; Martin H Bluth; Michael E Zenilman; Matthew R Pincus
Journal:  Cancer Ther       Date:  2007

8.  Apamin as a template for structure-based rational design of potent peptide activators of p53.

Authors:  Chong Li; Marzena Pazgier; Min Liu; Wei-Yue Lu; Wuyuan Lu
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

9.  Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response.

Authors:  Hua-Wen Sun; Qi-Bing Tang; Yong-Jun Cheng; Sheng-Qian Zou
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

10.  Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.

Authors:  Tohru Yamada; Masatoshi Goto; Vasu Punj; Olga Zaborina; Mei Ling Chen; Kazuhide Kimbara; Dibyen Majumdar; Elizabeth Cunningham; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.